Skip to main content
Header logo
  • Contact
  • Please fill out this field
  • Company Open link menu
    Company
    • About MEI Pharma
    • Management
    • Board of Directors
    • Our Mission and Commitment
    • Collaborations
  • Focus Open link menu
    Focus
    • Our Focus
    • Hematologic Malignancies
    • Solid Tumors
  • Pipeline Open link menu
    Pipeline
    • Programs
    • Pipeline Overview
    • Voruciclib
    • ME-344
    • More Information
    • Clinical Trials
    • Collaborations
    • Publications
  • Patients Open link menu
    Patients
    • Patients & Caregivers Overview
    • Clinical Trials
  • Investors Open link menu
    Investors
    • Investor Overview
    • Investor Summary
    • Financial Information
    • SEC Filings
    • Quarterly Results
    • Annual Reports
    Investors
    • Events & Presentations
    • Events Calendar
    • Presentations
    • Stock Information
    • Analyst Coverage
    • Stock Quote & Chart
    • Historical Stock Lookup
    Investors
    • Corporate Governance
    • Governance Documents
    • Board of Directors
    • Committee Composition
    • Environment, Social, and Governance
    • Investor Resources
    • Email Alerts
    • Contact IR
  • News & Media Open link menu
    News & Media
    • Press Releases
  • Careers
Please fill out this field
Press Releases

Press Releases

Breadcrumbs

  • Home
  • News & Media
  • Press Releases
2023 2022 2021 2020 2019 2018 2017 2016 2015
More
Date Title Download
Jul 13 2023 MEI Pharma Postpones Special Meeting of Shareholders PDF
Jul 11 2023 MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals PDF
Jul 7 2023 MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals PDF
Jul 5 2023 MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals PDF
Jun 29 2023 MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals PDF
Jun 27 2023 MEI Pharma Responds to Anson and Cable Car PDF
Jun 15 2023 MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates PDF
Jun 13 2023 MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor PDF
Jun 2 2023 MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor PDF
Jun 1 2023 MEI Pharma Board of Directors Rejects Unsolicited Proposal PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Sep 1 2022 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Sep 1 2022 MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022 PDF
Aug 1 2022 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Jul 18 2022 MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy PDF
Jul 1 2022 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Jun 22 2022 MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer PDF
Jun 10 2022 MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress PDF
Jun 4 2022 MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 PDF
Jun 1 2022 MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PDF
May 26 2022 MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022 PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Sep 22 2021 MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference PDF
Sep 3 2021 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Sep 2 2021 MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights PDF
Sep 2 2021 MEI Pharma to Present at Two Healthcare Conferences PDF
Aug 26 2021 MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021 PDF
Aug 17 2021 MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma PDF
Aug 5 2021 MEI Pharma Announces Planned Chief Financial Officer Transition PDF
Aug 2 2021 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF
Jul 7 2021 MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer PDF
Jul 1 2021 MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
May 26 2020 MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program PDF
May 14 2020 MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress PDF
May 13 2020 Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes PDF
May 13 2020 MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies; Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program PDF
May 7 2020 MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights PDF
Apr 14 2020 MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors PDF
Apr 14 2020 MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401 PDF
Apr 8 2020 MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference PDF
Mar 31 2020 MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma PDF
Feb 6 2020 MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Jul 3 2019 MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors PDF
Jun 22 2019 MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML) PDF
Jun 3 2019 MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
Jun 1 2019 MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
May 31 2019 MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference PDF
May 15 2019 MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
May 9 2019 MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights PDF
Apr 2 2019 MEI Pharma to Present at the 18th Annual Needham Healthcare Conference PDF
Mar 12 2019 MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference PDF
Feb 14 2019 Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood Advance PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Aug 23 2018 MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018 PDF
Jul 16 2018 MEI Pharma Promotes David M. Urso to Chief Operating Officer PDF
Jun 15 2018 MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress PDF
Jun 4 2018 MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
Jun 4 2018 MEI Pharma Presents Clinical Data for ME-344 in HER2 Negative Breast Cancer Patients at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
May 31 2018 MEI Pharma and Helsinn Group Announce Successful Interim Analysis of Pracinostat/Azacitidine Phase 2 Combination Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients PDF
May 16 2018 MEI Pharma to Present Clinical Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting PDF
May 14 2018 MEI Pharma Announces $75 Million Private Placement PDF
May 9 2018 MEI Pharma Reports Third Quarter Fiscal Year 2018 Results PDF
Mar 14 2018 MEI Pharma To Present at Two Upcoming Investor Conferences PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Jun 14 2017 Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome PDF
Jun 5 2017 Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PDF
May 31 2017 MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma PDF
May 18 2017 Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia PDF
May 4 2017 MEI Pharma Reports Third Quarter Fiscal Year 2017 Results PDF
Apr 3 2017 MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer PDF
Mar 28 2017 MEI Pharma to Present at Needham Healthcare Conference PDF
Mar 14 2017 MEI Pharma to Present at Oppenheimer Healthcare Conference PDF
Feb 8 2017 MEI Pharma Reports Second Quarter Fiscal Year 2017 Results PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Apr 5 2016 MEI Pharma to Present at Needham Healthcare Conference PDF
Feb 1 2016 MEI Pharma to Present at BIO CEO & Investor Conference PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2
Date Title Download
Jun 12 2015 MEI Pharma Reports Updated Results from Phase II Study of Pracinostat and Azacitidine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia PDF
May 6 2015 MEI Pharma to Present at Bank of America Merrill Lynch Health Care Conference PDF
May 4 2015 MEI Pharma's Mitochondrial Inhibitor ME-344 Shows Enhanced Anti-Tumor Activity in Combination with Tyrosine-Kinase Inhibitor in Pre-Clinical Studies PDF
Apr 1 2015 MEI Pharma to Present at Needham Healthcare Conference PDF
Mar 23 2015 MEI Pharma Announces Top-Line Data From Randomized Phase II Clinical Study Of Pracinostat In Front-Line Myelodysplastic Syndrome PDF
Feb 26 2015 MEI Pharma to Present at Cowen and Company Health Care Conference PDF

Pagination

  • First page
  • Previous page
  • Page 1
  • Current page 2

Connect with Us.

© MEI Pharma, Inc.
11455 El Camino Real, Suite 250
San Diego, CA 92130
Keep up to date on social media

Footer

  • Site Map
  • Privacy Notice
  • Terms of Use
  • Cookies Policy
  • Contact
  • Cookie Settings
  • Copyright 2023
DOCPDFPDFXBRLXLS